This trial is active, not recruiting.

Condition relapse schizophrenia
Treatment itareps
Sponsor Prague Psychiatric Center
Start date August 2012
End date July 2014
Trial size 150 participants
Trial identifier NCT01885923, ITAREPS 2.0, NT/13292 - 3


THE AIM OF THE PROJECT The main aim lies in the prevention of frequent relapses typical for schizophrenia and schizoaffective disorder by means of simple, highly cost-effective information technology-aided approach RESEARCH HYPOTHESIS A the end of 18 months study duration, patients in the active group enrolled in ITAREPS will demonstrate statistically significantly reduced risk of hospitalization, decreased number of hospitalization days and reduced direct inpatient costs in comparison to control group not using the program.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose prevention
(Active Comparator)
Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
itareps Information Technology Aided Relaps Prevention in Schizophrenia
Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
(No Intervention)
In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.

Primary Outcomes

Primary Objective: The hospitalization-free survival rate at 18 months in active group compared to the control group.
time frame: 18 months

Secondary Outcomes

Number of psychiatric hospitalization days
time frame: 18months
Direct impatient costs
time frame: 18months
Direct cost of outpatient antipsychotic medication
time frame: 18months
Cumulative exposition to antipsychotic medication in both active ITAREPS and control groups
time frame: 18months

Eligibility Criteria

Male or female participants from 18 years up to 60 years old.

Inclusion Criteria: For entry into the study, the following criteria MUST be met: - Men and women, ages 18 to 60 years, inclusive. - A diagnosis of schizophrenia or schizoaffective disorder according to ICD-10 classification. - Having at least TWO psychiatric hospitalization for psychosis before the study enrollment. - Severity (CGI-S) ≤ 3 at study Visit 1. - All patients must be on stable doses of antipsychotic medication during the study entry. Exclusion Criteria: - Organic mental disorder, - mental disorder due to psychoactive substance use or mental retardation. - Participation in another relapse prevention program. - Hayward compliance rating scale score < 2 at Visit 1.

Additional Information

Official title Prospective, Randomized, Open, Controlled Study With Information and Telecommunication Technology-aided Relapse Prevention Program in Schizophrenia.
Description The ITAREPS 2.0 program employs telecommunication and information technologies in order to detect fluctuations in longitudinal mental health status of patient with schizophrenia and thus signalize the very early stages of prodromes preceding relapse. This approach opens an avenue towards early pharmacological intervention. Subjects (150 patients with diagnosis of schizophrenia and schizoaffective disorder and their family members) will be randomized at a 1:1 ratio into the active or control group. Participants from the active group will be completing two separate versions of the 10-item Early Warning Signs Questionnaire (EWSQ) upon a weekly SMS request generated automatically by the system during 18 months study duration. In this group, automatically generated e-mail alert message feedback to the investigator will be activated in case of prodrome detection, prompting investigator to antipsychotic dose increase by 20%. The control (treatment-as-usual) group will not use ITAREPS system.
Trial information was received from ClinicalTrials.gov and was last updated in July 2013.
Information provided to ClinicalTrials.gov by Prague Psychiatric Center.